31-Jul-2026
Glaukos Corp. Earnings Call Highlights Robust Growth
TipRanks (Fri, 31-Jul 8:27 PM ET)
TipRanks (Fri, 31-Jul 2:00 AM ET)
Glaukos hits new all-time high on Q2 results, raised 2026 revenue guidance
Seeking Alpha News (Thu, 30-Jul 1:26 PM ET)
Glaukos Delivers Record Q2 Sales, Lifts 2026 Revenue Guidance as iDose TR and Epioxa Fuel Growth
Market Chameleon (Thu, 30-Jul 7:53 AM ET)
Truist Financial Keeps Their Buy Rating on Glaukos (GKOS)
TipRanks (Thu, 30-Jul 7:59 AM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Thu, 30-Jul 7:11 AM ET)
Piper Sandler Sticks to Their Buy Rating for Glaukos (GKOS)
TipRanks (Thu, 30-Jul 6:57 AM ET)
TipRanks (Thu, 30-Jul 6:50 AM ET)
Analysts Offer Insights on Healthcare Companies: Glaukos (GKOS) and MannKind (MNKD)
TipRanks (Thu, 30-Jul 6:40 AM ET)
Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Humana (HUM)
TipRanks (Thu, 30-Jul 6:30 AM ET)
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Glaukos trades on the NYSE stock market under the symbol GKOS.
As of July 31, 2026, GKOS stock price declined to $166.72 with 920,523 million shares trading.
GKOS has a beta of 0.27, meaning it tends to be less sensitive to market movements. GKOS has a correlation of 0.00 to the broad based SPY ETF.
GKOS has a market cap of $9.83 billion. This is considered a Mid Cap stock.
Last quarter Glaukos reported $186 million in Revenue and -$.14 earnings per share. This beat revenue expectation by $35 million and exceeded earnings estimates by $.09.
In the last 3 years, GKOS traded as high as $184.00 and as low as $59.22.
The top ETF exchange traded funds that GKOS belongs to (by Net Assets): IJR, VTI, IWM, VB, VBK.
GKOS has outperformed the market in the last year with a price return of +93.7% while the SPY ETF gained +19.4%. GKOS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +16.0% and +6.3%, respectively, while the SPY returned +4.2% and +0.5%, respectively.
GKOS support price is $162.33 and resistance is $174.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GKOS shares will trade within this expected range on the day.